Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 7/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429121 | 1.00 | HMGCR (0.45) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL3023466 | 0.97 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL59533 | 0.95 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL2571403 | 0.84 | TSHR (0.38) | HMGCRPTPN7TSHR | |
| SCHEMBL5168900 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5170459 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5169808 | 0.83 | HMGCR (0.41) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL2118927 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5167000 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL | |
| SCHEMBL5166824 | 0.82 | HMGCR (0.43) | HMGCRPTPN7TSHRTHRBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085699-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2024-04-25 | — | — | WO | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| EP-3512516-A1 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME | Cipolli, Marco (IT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050706-A1 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME | CIPOLLI MARCO (IT) | 2018-03-22 | — | — | WO | disclosed |
| EP-3153161-A1 | SMALL MOLECULE INHIBITORS OF TRPA1 | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2017-04-12 | — | — | EP | disclosed |
| CN-104056278-B | 1,2,4-oxadiazole benzoic acid compounds | PTC 治疗公司 | 2017-01-18 | — | — | CN | disclosed |
| EP-2706995-B1 | SMALL MOLECULE INHIBITORS OF TRPA1 | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2604598-B1 | TRPV1 antagonists and uses thereof | PURDUE PHARMA LP (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2797912-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | Purdue Pharma LP (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2709609-A1 | HETEROCYCLIC COMPOUNDS | Shionogi & Co., Ltd. (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1542991-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | Euro-Celtique, S.A. (LU) | 2005-06-22 | — | — | EP | disclosed |
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1507528-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | Signal Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | HMGCR 163/4885PTPN7 1853/4885TSHR 4476/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | HMGCR 163/4885PTPN7 1853/4885TSHR 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.